TGM2 has been identified as an important factor in variant types of cancer (such as gastric cancer, ovarian cancer, colorectal cancer, breast cancer, etc.), and importantly its elevated expression level in tumor tissues is commonly linked to worse disease outcomes and poor survival rates (Table 1). Here, TGM2 is linked to ovarian carcinoma.